Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own0.20% Shs Outstand85.10M Perf Week0.64%
Market Cap66.80M Forward P/E- EPS next Y-0.46 Insider Trans- Shs Float84.43M Perf Month-10.12%
Income-26.40M PEG- EPS next Q-0.14 Inst Own62.60% Short Float1.30% Perf Quarter-13.78%
Sales3.30M P/S20.24 EPS this Y-9.10% Inst Trans20.64% Short Ratio3.61 Perf Half Y-36.69%
Book/sh0.16 P/B4.91 EPS next Y6.10% ROA-66.80% Target Price2.08 Perf Year-67.96%
Cash/sh0.36 P/C2.19 EPS next 5Y- ROE-175.60% 52W Range0.70 - 3.72 Perf YTD-12.53%
Dividend- P/FCF- EPS past 5Y42.80% ROI-195.20% 52W High-79.83% Beta2.36
Dividend %- Quick Ratio1.90 Sales past 5Y8.40% Gross Margin- 52W Low7.21% ATR0.06
Employees39 Current Ratio1.90 Sales Q/Q-22.20% Oper. Margin- RSI (14)39.67 Volatility8.89% 7.54%
OptionableYes Debt/Eq0.64 EPS Q/Q64.00% Profit Margin- Rel Volume0.28 Prev Close0.79
ShortableYes LT Debt/Eq0.16 EarningsMar 10 BMO Payout- Avg Volume303.14K Price0.75
Recom2.60 SMA20-9.09% SMA50-13.41% SMA200-51.08% Volume53,399 Change-4.39%
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Jan-08-16 12:18PM  Edited Transcript of SNSS earnings conference call or presentation 5-Nov-15 4:00pm GMT
Jan-04-16 07:00AM  Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML GlobeNewswire
Dec-24-15 07:33AM  Will Sunesis Pharmaceuticals (SNSS) Continue to Surge Higher?
Dec-21-15 04:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Sunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriters Over-Allotment Option GlobeNewswire
Dec-17-15 10:58AM  Sunesis Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-16-15 05:01PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to
08:20AM  Sunesis Announces Pricing of $25 Million Offering of Securities GlobeNewswire
Dec-08-15 01:17PM  SUNESIS PHARMACEUTICALS INC Financials
07:00AM  Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe GlobeNewswire
Dec-07-15 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial in AML at ASH Annual Meeting GlobeNewswire -6.59%
Dec-06-15 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase 1/2 Trial of Vosaroxin in MDS and VALOR Analysis of Baseline Safety Predictors at ASH Annual Meeting GlobeNewswire
Dec-03-15 07:00AM  Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia GlobeNewswire -6.02%
Dec-01-15 07:00AM  Sunesis Pharmaceuticals Announces First Patient Treated in Indiana University Pilot Study of Vosaroxin and Cytarabine in Adults Age 60 Years and Older With Previously Untreated AML GlobeNewswire -6.11%
Nov-30-15 07:00AM  Sunesis Pharmaceuticals Announces European Patent Covering Vosaroxin Combination Use in AML and Other Hematologic Malignancies GlobeNewswire +8.42%
Nov-28-15 02:33PM  Sunesis Pharmaceuticals, Inc. (SNSS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-27-15 05:21PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Nov-25-15 02:31PM  ReachLocal Inc. (RLOC): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-09-15 07:00AM  Sunesis Pharmaceuticals Presents Preclinical Data From Its BTK and PDK1 Inhibitor Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Nov-05-15 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
09:57AM  Sunesis reports 3Q loss
09:27AM  Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting GlobeNewswire
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights GlobeNewswire
Nov-04-15 06:00PM  Sunesis Pharmaceuticals Announces Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at the 2015 Chemotherapy Foundation Symposium GlobeNewswire
Oct-29-15 07:00AM  Sunesis to Host Conference Call on November 5th to Discuss Third Quarter 2015 Financial Results and Recent Highlights GlobeNewswire
Oct-27-15 04:28PM  Sunesis Pharmaceuticals Announces Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-15-15 04:05PM  Sunesis Pharmaceuticals Announces Oral Presentation of VALOR Analysis at the 77th Annual Meeting of the Japanese Society of Hematology GlobeNewswire +10.31%
Oct-09-15 04:04PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-07-15 04:01PM  Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End GlobeNewswire
Oct-01-15 11:04AM  Sunesis Pharmaceuticals, Inc. Earnings Q2, 2015 +17.28%
Sep-28-15 01:01PM  Why Smart Traders Bought the Hillary Clinton Biotech Stock Dip, and Which Stocks They Are Placing Their Bets On Accesswire -12.14%
Sep-10-15 09:00AM  BioWatch's Alan Leong Interviewed by The Life Sciences Report Marketwired
06:07AM  5 Stocks Under $10 Set to Soar at TheStreet
Aug-11-15 01:48PM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet +6.40%
Aug-10-15 02:08PM  IBB claws its way back +15.74%
Aug-05-15 07:00AM  Sunesis Pharmaceuticals to Present at the 2015 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-04-15 04:01PM  Sunesis Announces Publication of Vosaroxin Phase 3 VALOR Trial Results in The Lancet Oncology GlobeNewswire
Aug-01-15 08:09PM  10-Q for Sunesis Pharmaceuticals, Inc. at Company Spotlight
Jul-30-15 08:02AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +10.53%
07:46AM  Sunesis reports 2Q loss
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights GlobeNewswire
Jul-28-15 09:25AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5% - Tale of the Tape +11.43%
Jul-27-15 12:00PM  GPM Announces Investigation of Sunesis Pharmaceuticals, Inc. Business Wire +9.49%
Jul-24-15 07:05PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Sunesis Pharmaceuticals, Inc. Business Wire -72.36%
06:17PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Sunesis Pharmaceuticals, Inc. on Behalf of Investors Business Wire
02:23PM  Investigation of Sunesis Pharmaceuticals, Inc. Announced by The Law Offices of Howard G. Smith Business Wire
01:21PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws Business Wire
11:38AM  Shareholder Alert: AF&T Announces That It Has Been Retained to Investigate Claims on Behalf of Investors in Sunesis Pharmaceuticals, Inc. Business Wire
09:45AM  Is This the End of Sunesis? at 24/7 Wall St.
08:45AM  Top Analyst Upgrades and Downgrades: Amazon, GM, SolarCity, Sunesis, United Continental, Disney, Valero and More at 24/7 Wall St.
07:39AM  Sunesis Pharma downgraded by ROTH Capital and Cantor Fitzgerald
Jul-23-15 06:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS Accesswire
05:37PM  Sunesis tumbles as FDA says it won't approve cancer drug
04:20PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:06PM  Sunesis Pharmaceuticals Announces Regulatory Update GlobeNewswire
Jul-22-15 03:30PM  Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Jul-21-15 06:31PM  BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog
05:00PM  Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
Jul-20-15 11:08AM  Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue? - Tale of the Tape
Jul-02-15 09:32AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 8% - Tale of the Tape
Jul-01-15 07:00AM  Sunesis to Present at Cantor Fitzgerald's Inaugural Healthcare Conference GlobeNewswire +7.97%
Jun-23-15 09:25AM  Sunesis (SNSS) Worth Watching: Stock Moves 9.1% Higher - Tale of the Tape
Jun-19-15 07:35AM  Sunesis Pharmaceuticals (SNSS) Shares March Higher, Can It Continue? - Tale of the Tape
Jun-15-15 09:35AM  These Biotech Stocks Could Deliver Big Returns for Investors Accesswire
Jun-13-15 03:40AM  Edited Transcript of SNSS conference call or presentation 12-Jun-15 2:00pm GMT
Jun-12-15 03:08PM  How to Trade 5 of the Market's Most Active Stocks -- Buy, Hold or Sell? at TheStreet
11:25AM  Is Sunesis Coming Back From the Dead? at 24/7 Wall St.
10:00AM  Sunesis Pharmaceuticals, Inc. Presentations of VALOR Data Call scheduled for 10:00 am ET today
07:00AM  Sunesis Pharmaceuticals Presents New Data From VALOR Evaluating Vosaroxin in Older Patients With Acute Myeloid Leukemia at the 20th Congress of the European Hematology Association GlobeNewswire
Jun-10-15 04:04PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-31-15 09:00AM  Sunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual Meeting GlobeNewswire
May-21-15 08:09AM  Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association GlobeNewswire
May-15-15 09:10AM  The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update Marketwired +6.44%
May-14-15 07:00AM  Sunesis Pharmaceuticals Announces Presentation of VALOR Data at the 2015 ASCO Annual Meeting GlobeNewswire
May-13-15 07:00AM  Sunesis to Present at the 2015 UBS Global Health Care Conference GlobeNewswire +9.95%
May-07-15 08:09PM  10-Q for Sunesis Pharmaceuticals, Inc. at Company Spotlight
May-06-15 08:12PM  10-K for Sunesis Pharmaceuticals, Inc. at Company Spotlight
May-05-15 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today -7.83%
08:39AM  Sunesis reports 1Q loss
08:02AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:01AM  Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights at noodls
07:07AM  Q1 2015 Sunesis Pharmaceuticals Inc Earnings Release - Time Not Supplied
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights GlobeNewswire
Apr-28-15 07:00AM  Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2015 Financial Results and Recent Highlights GlobeNewswire
Apr-10-15 06:01AM  Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind at TheStreet
Apr-02-15 02:33PM  Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report Marketwired
Mar-31-15 12:41PM  Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMeds Recent Activity in Biotech at Insider Monkey
Mar-24-15 02:13PM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Mar-23-15 03:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Mar-12-15 04:48PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and +6.42%
11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today
08:11AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights at noodls
07:27AM  Sunesis reports 4Q loss
07:07AM  Q4 2014 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights GlobeNewswire
Mar-05-15 01:42PM  3 Biotech stocks Under $10 to Trade for Breakouts at TheStreet +6.02%
07:00AM  Sunesis to Host Conference Call on March 12th to Discuss Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights GlobeNewswire
Mar-02-15 09:07AM  Sunesis Announces Amendment to Loan Agreement at noodls
07:00AM  Sunesis Announces Amendment to Loan Agreement GlobeNewswire
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Misfeldt DaytonDirectorDec 21Buy0.841,750,0001,470,0007,234,441Dec 21 09:31 PM
Swisher Daniel N JRPresident and CEOAug 25Buy1.0112,21612,338199,736Aug 26 07:54 PM
Swisher Daniel N JRPresident and CEOAug 24Buy1.0112,78412,912187,520Aug 26 07:54 PM
Swisher Daniel N JRPresident and CEOJul 24Buy1.0225,00025,458174,336Jul 28 09:52 PM
Misfeldt DaytonDirectorJul 24Sale3.46635,7022,200,24298,713Dec 21 09:25 PM
BAY CITY CAPITAL LLC10% OwnerJul 24Sale3.46635,7022,199,5295,267,598Jul 28 06:32 PM
Ketchum Steven BDirectorJul 24Sale3.466,35821,98980,827Jul 28 09:53 PM
BJERKHOLT ERICEVP, CFO & Corp. SecretaryJul 24Sale3.466,35821,98980,395Jul 28 09:52 PM
Swisher Daniel N JRPresident and CEOJul 24Sale3.4612,71543,975142,869Jul 28 09:52 PM